» Articles » PMID: 30767695

Blood-brain Barrier Receptors and Transporters: an Insight on Their Function and How to Exploit Them Through Nanotechnology

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2019 Feb 16
PMID 30767695
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The blood-brain barrier (BBB) is a highly limiting barrier that prevents the brain from contacting with several circulating molecules, including harmful agents. However, certain systemic nutrients and macromolecules are able to cross the BBB and reach the brain parenchyma, involving the interaction with multiple receptors and/or transporters at the BBB surface. Nanotechnology allows the creation of drug vehicles, functionalized with targeting ligands for binding specific BBB receptors and/or transporters, hence triggering the transport through this biobarrier.

Areas Covered: This review focuses the BBB receptors/transporters to be exploited in regard to their overall structure and biologic function, as well as their role in the development of strategies envisaging drug delivery to the brain. Then, the interplay between the targeting of these BBB receptors/transporters and nanotechnology is explored, as they can increase by several-fold the effectiveness of brain-targeted therapies.

Expert Opinion: Nanomedicine may be particularly useful in brain drug delivery, mainly due to the possibility of functionalizing nanoparticles to target specific receptors/transporters. Since the BBB is endowed with numerous receptors and transporters responsible for regulating the proper metabolic activity of the brain, their targeting can be a promising bypass strategy to circumvent the hurdle that the BBB represents for brain drug delivery.

Citing Articles

Nanotherapy of Glioblastoma-Where Hope Grows.

Grzegorzewski J, Michalak M, Woloszczuk M, Bulicz M, Majchrzak-Celinska A Int J Mol Sci. 2025; 26(5).

PMID: 40076445 PMC: 11898975. DOI: 10.3390/ijms26051814.


T Cells Trafficking into the Brain in Aging and Alzheimer's Disease.

Ma Y, Cao J, Zhang Y, Su X, Jing Y, Gao L J Neuroimmune Pharmacol. 2024; 19(1):47.

PMID: 39180590 DOI: 10.1007/s11481-024-10147-5.


Upregulation of Transferrin Receptor 1 (TfR1) but Not Glucose Transporter 1 (GLUT1) or CD98hc at the Blood-Brain Barrier in Response to Valproic Acid.

Helgudottir S, Johnsen K, Routhe L, Rasmussen C, Thomsen M, Moos T Cells. 2024; 13(14.

PMID: 39056763 PMC: 11275047. DOI: 10.3390/cells13141181.


The Basic Requirement of Tight Junction Proteins in Blood-Brain Barrier Function and Their Role in Pathologies.

Dithmer S, Blasig I, Fraser P, Qin Z, Haseloff R Int J Mol Sci. 2024; 25(11).

PMID: 38891789 PMC: 11172262. DOI: 10.3390/ijms25115601.


Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma.

Branco F, Cunha J, Mendes M, Vitorino C, Sousa J ACS Nano. 2024; 18(26):16359-16394.

PMID: 38861272 PMC: 11223498. DOI: 10.1021/acsnano.4c01790.